

AllStent Appoints Dutch Vascular Surgeon Dr. Joost van Herwaarden MD, to CAB

"Joost's clinical-surgical and research activities focus on treatment of aortic pathology, including primarily aneurysms and dissections, and has a special interest in new developments in image-guided therapies, so it's a perfect fit for at this time in our product and clinical development priorities." Paul Chipperton, CEO

Date of release: Monday Feb-10

Locations: Toronto, Canada; and Milan, Italy

AllStent, with Business, Finance and Regulatory operations in Toronto, Canada; and Research & Development in Milan, Italy, is pleased to announce the appointment of Dr Adam Power MD to our Clinical Advisory Board (CAB).

Prof. Joost A. van Herwaarden, MD, PhD is Full Professor of Vascular Surgery and Head of the department of Vascular Surgery at the University Medical Center Utrecht (Netherlands). His clinical-surgical and research activities focus on treatment of aortic pathology, including primarily aneurysms and dissections. Since 2012 he has a close collaboration with Philips on the development of, and translation to, clinical use of Fiber Optical RealShape (FORS) technology. In 2018 he was the PI of the FORS first-in-human study. There is a longstanding collaboration for research on aortic pathology treatment with the Policlinico Università degli Studi di Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan) and the Vascular Surgery departments of the University of Michigan and Harvard Medical School (USA). He is an active reviewer of many peer-reviewed medical journals and was part of the writing committee of Aortic Disease guidelines of the ESVS, and of the 2023 Clinical Practice Guidelines on Radiation Safety (ESVS).

LINKS

www.allstent.com

https://www.polimi.it/

https://research.umcutrecht.nl/researchers/joost-a-van-herwaarden/

ABOUT AllStent

AllStent was formed in July 2024 as a spin-out of Politecnico di Milano, Italy (Polimi), cofounded by a young female team of PhD's and Post-Docs from Dr Migliavacca's *in silico* medicine group in Computational Biomechanics. Just since 2019, with >70 academic peerreviewed publications on the topics of cardiovascular and neurovascular mechanics, the company was formed to commercialise in the area of greatest need, pre-operative planning and post-operative complication assessment of complex TEVAR surgeries.

Delivering an unmet market pull directly from surgeons, AllStent is offering unique patientspecific high-fidelity 3D-simulations and accurate "digital twins" of the anatomy and TEVAR procedure, range of optimal stent-grafts, and best-fit and post-deployment risk analysis.

ALLSTENT MEDIA CONTANT



Paul Chipperton

E: CEO@allstent.com

T: +1 647 291 8545